Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI – Get Free Report) saw a significant increase in short interest during the month of April. As of April 15th, there was short interest totalling 1,990,000 shares, an increase of 48.5% from the March 31st total of 1,340,000 shares. Based on an average trading volume of 987,100 shares, the short-interest ratio is presently 2.0 days.
Analyst Ratings Changes
Separately, StockNews.com began coverage on shares of Brainstorm Cell Therapeutics in a research report on Wednesday, March 27th. They set a “sell” rating for the company.
Check Out Our Latest Research Report on Brainstorm Cell Therapeutics
Hedge Funds Weigh In On Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics Price Performance
BCLI traded up $0.01 during midday trading on Monday, reaching $0.55. 57,458 shares of the company’s stock were exchanged, compared to its average volume of 958,317. The business’s 50-day moving average price is $0.48 and its 200 day moving average price is $0.33. The stock has a market capitalization of $37.44 million, a PE ratio of -1.31 and a beta of 0.27. Brainstorm Cell Therapeutics has a 1-year low of $0.13 and a 1-year high of $3.34.
Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Free Report) last posted its quarterly earnings data on Monday, April 1st. The biotechnology company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.04. As a group, analysts expect that Brainstorm Cell Therapeutics will post -0.28 EPS for the current fiscal year.
About Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.
Featured Articles
- Five stocks we like better than Brainstorm Cell Therapeutics
- What Does a Stock Split Mean?
- The 3 Hottest Insiders Buys This Month
- Dividend Capture Strategy: What You Need to Know
- What Bulls and Bears May Be Getting Wrong about SOFI Stock
- How to Use the MarketBeat Stock Screener
- Microsoft Analysis: Trends, Predictions & Investment Insight
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.